Value of F-18 FDG PET/CT for the Prediction of EGFR Mutation in Lung Cancer Patients

• Globally, lung cancer cases and deaths are rising. In 2018, GLOBOCAN estimated 2.09 million new cases (11.6% of total cancer cases) and 1.76 million deaths (18.4% of total cancer deaths). It is the most frequent cancer and cause of cancer death in men.
• Epidermal growth factor receptor (EGFR) mutations are the second most common oncogenic driver event in non-small cell lung cancer (NSCLC) and classical activating mutations are well defined as strong predictors for good clinical response to EGFR tyrosine kinase inhibitors (EGFRi).
• Over the last decade, the introduction of tyrosine-kinase inhibitors (TKIs) has showed a remarkable paradigm shift in the treatment of non-small cell lung cancer (NSCLC). However, genetic testing is sometimes unavailable.
• Data from previous studies that have investigated the value of F-18 FDG PET/CT for predicting EGFR status are conflicting.

Inclusion criteria

• NSCLC patients who underwent EGFR mutation testing.
• All patients ≥ 18 years.

Exclusion criteria

• Time interval between EGFR sampling and PET/CT more than 1 month.
• Patients had been treated before sampling for the gene alteration analysis
• Patients with glucose level < 200 mg/dl.